

Ramatercept

Cat. No.:	HY-P99818
CAS No.:	1169766-01-1
Target:	TGF- β Receptor
Pathway:	TGF-beta/Smad
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Ramatercept is a soluble ActRIIB receptor and can be used as a soluble activin receptor 2 (ACVR2) antagonist. Ramatercept inhibits the signal pathway of muscle growth inhibition and has potential application in muscle atrophy ^{[1][2][3]} .
IC ₅₀ & Target	soluble activin receptor 2, ACVR2 ^[2]
In Vivo	Ramatercept (10 mg/kg; s.c.; three times a week for 5 weeks) significantly increases the muscle mass of mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Fariello R G, et al. A novel Biological (FOX-115) improves endurance of motor performances in old mice (P2. 4-033)[J]. 2019.
- [2]. Feike Y, et al. Advances in research on pharmacotherapy of sarcopenia. Aging Med (Milton). 2021 Aug 9;4(3):221-233.
- [3]. Louvel É. Dopage: nouveaux médicaments influant sur la biogenèse musculaire et mitochondriale[J]. 2019.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA